Construction of Oka varicella vaccine expressing human immunodeficiency virus env antigen.
Oka varicella vaccine has been used to confer active immunity to varicella-zoster virus (VZV) in healthy and immunocompromised hosts. Based on its attenuated nature, Oka varicella vaccine expressing human immunodeficiency virus (HIV) env antigen was constructed by inserting the HIVenv gene into the viral genome and its immunogenicity was assessed in guinea pigs. The HIVenv gene encoding 296-463 amino acids was inserted between the sequences of the hepatitis B surface antigen and the thymidine kinase gene of the cloned plasmid and the recombinant virus was isolated by cotransfection of the chimeric plasmid with viral DNA. Insertion of the HIVenv gene into the viral genome was confirmed by PCR and sequencing of the viral genome of the recombinant virus. The recombinant virus expressed 30k HIVenv fusion protein in its infected cells. In guinea pigs, immunization with the recombinant virus induced an antibody response to both the HIV antigen and the V3 peptide of gp120 as well as VZV gE:gI. Cell-mediated immunity to the HIV antigen and gE:gI was assessed by the cutaneous reaction representing delayed type hypersensitivity. Immunized guinea pigs responded well to both the HIV antigen and gE:gI. Thus the recombinant Oka varicella vaccine expressing the HIVenv antigen induced both a humoral and cell-mediated immunity to the HIV antigen similar to VZV as Oka varicella vaccine induces humoral and cell-mediated immunity to VZV in the vaccinees. This recombinant Oka varicella vaccine expressing the HIVenv antigen may be evaluated for its immunogenicity as one of the AIDS vaccine candidates.
Shiraki
K
K
Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. kshiraki@toyama-mpu.ac.jp
Sato
H
H
Yoshida
Y
Y
Yamamura
J I
JI
Tsurita
M
M
Kurokawa
M
M
Kageyama
S
S
D016915:AIDS Vaccines / Q000276:immunology; D000818:Animals; D000917:Antibody Formation; D019433:Chickenpox Vaccine / Q000235:genetics* / Q000276:immunology; D005822:Genetic Vectors; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000097:blood; D015488:HIV Antigens / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D007114:Immunization; D010446:Peptide Fragments / Q000276:immunology; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins / Q000276:immunology; D014760:Viral Fusion Proteins / Q000096:biosynthesis / Q000276:immunology
D016915:AIDS Vaccines; D019433:Chickenpox Vaccine; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; C056913:glycoprotein E, varicella-zoster virus